Supplementary data: Testosterone suppression in the treatment of recurrent or metastatic prostate cancer – A Canadian consensus statement

摘要

Accurate measurement of testosterone levels duringandrogen-deprivation therapy (ADT) is critical to providing optimal care for men with prostate cancer.The following tables provide guidance for sample collectionand handling, direction on data reporting (SupplementaryTable 1) and specifications for the use of mass spectrometry for assay of testosterone in serum samples in this context (Supplementary Table 2). This document is intended tofacilitate dialogue between clinicians and clinical laboratory staff by: 1) providing the details needed to assess thecapacity for a selected assay to accurately measure serumtestosterone levels ≤0.7 nmol/l; 2) indicating steps to ensureanalyte (i.e., testosterone) preservation in collected samples;and 3) providing detailed settings to use in performing theliquid chromatography tandem mass spectrometry (LC-MS/MS)-based assay.